Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | EYA2 | O00167 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8602002 | 0.97 | FFAR3 (0.45) | FFAR3TDP1EYA2APPACE | |
| SCHEMBL16264142 | 0.91 | TDP1 (0.39) | FFAR3TDP1EYA2APPACE | |
| SCHEMBL5080836 | 0.85 | CA12 (0.43) | FFAR3TDP1EYA2APPACE | |
| SCHEMBL12527092 | 0.82 | FFAR3 (0.36) | FFAR3TDP1EYA2APPACE | |
| SCHEMBL17816490 | 0.82 | FFAR3 (0.36) | FFAR3TDP1EYA2APPACE | |
| SCHEMBL16330708 | 0.80 | ALDH1A1 (0.49) | FFAR3TDP1EYA2APPACE | |
| SCHEMBL16264141 | 0.80 | LMNA (0.39) | FFAR3TDP1EYA2APPACE | |
| SCHEMBL265251 | 0.79 | FFAR3 (0.50) | FFAR3TDP1APPLMNATSHR | |
| SCHEMBL16172025 | 0.78 | TDP1 (0.39) | FFAR3TDP1EYA2APPACE | |
| SCHEMBL10042458 | 0.78 | ALDH1A1 (0.47) | FFAR3TDP1LMNAALDH1A1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | ENZON PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120115796-A1 | Novel Spacer Moiety for Poly(ehtylene Glycol) Modified Peptide Based Compounds | AFFYMAX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20070203066-A1 | Compositions and methods for inhibiting cellular proliferation | ENTREMED, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-0941120-A4 | BRANCHED PEPTIDE LINKERS | BRISTOL MYERS SQUIBB CO (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-0941120-A1 | BRANCHED PEPTIDE LINKERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1998019705-A1 | BRANCHED PEPTIDE LINKERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-14 | — | — | WO | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| CN-1097417-A | New heterogeneous ring compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-01-18 | — | — | CN | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | FFAR3 4528/4885TDP1 758/4885EYA2 3559/4885 |
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | VEGFA, MKI67, PCNA | FFAR3 3652/4885TDP1 1879/4885EYA2 3274/4885 |
| US-20120115796-A1 | Novel Spacer Moiety for Poly(ehtylene Glycol) Modified Peptide Based Compounds | NGLY1, HM13, YWHAZ | FFAR3 3823/4885TDP1 4525/4885EYA2 3000/4885 |
| US-20070203066-A1 | Compositions and methods for inhibiting cellular proliferation | MKI67, VEGFA, HDGF | FFAR3 4297/4885TDP1 4402/4885EYA2 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.